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Abstract 18 
Scope: Cranberries are rich in potentially bioactive (poly)phenols. The aim of this work was to 19 
investigate whether cranberry juice intake can improve vascular function in healthy men in a 20 
dose- and time-dependent manner, and to understand which of the circulating (poly)phenol 21 
metabolites correlate with vascular effects. 22 
Methods and results: A double-blind randomized controlled crossover trial was conducted in 10 23 
healthy males. Flow-mediated dilation (FMD), blood pressure, pulse wave velocity and 24 
augmentation index were investigated at baseline, 1, 2, 4, 6, and 8h post-consumption of 25 
cranberry juices containing 409, 787, 1238, 1534, and 1910 mg of total cranberry (poly)phenols 26 
(TP), and a control drink. Plasma (poly)phenol metabolites were analyzed by UPLC-Q-TOF MS 27 
using authentic standards. We observed dose-dependent increases in FMD at 1, 2, 4, 6, and 8h 28 
with a peak at 4h and maximal effects with juice containing 1238 mg TP. A total of 60 29 
metabolites were quantified in plasma after cranberry consumption. Twelve (poly)phenol 30 
metabolites significantly correlated with the increases in FMD, including ferulic and caffeic acid 31 
sulfates, quercetin-3-O-ß-D-glucuronide and a -valerolactone sulfate.  32 
Conclusion: (Poly)phenols in cranberry juice can improve vascular function in healthy males 33 
and this is linked to the presence of specific newly identified plasma metabolites.  34 
 35 
 36 
 37 
 38 
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Introduction 39 
Accumulating evidence from epidemiological and human intervention studies indicates that the 40 
cardiovascular health benefits of diets rich in berries are in part related to their (poly)phenol 41 
content [1]. Cranberries, in particular, are rich in proanthocyanidins, anthocyanins, and phenolic 42 
acids [2, 3]. 43 
A limited number of double blind randomized controlled trials (RCT) have investigated the 44 
effects of cranberry (poly)phenols on clinically relevant and accredited markers of vascular 45 
function, such as endothelial function, blood pressure, and arterial stiffness with mixed results 46 
[4-9]. Importantly, the study populations were mainly subjects at increased cardiovascular risk or 47 
manifest cardiovascular disease. Currently, it is unknown whether cranberry consumption can 48 
improve vascular function in healthy individuals and, if so, at which intake amount and which 49 
role (poly)phenols may play in this. 50 
Therefore, the major aim of this work was to investigate the time course and dose-dependent 51 
effects of cranberry (poly)phenols on endothelial function in healthy individuals, as determined 52 
by flow-mediated vasodilation (FMD; primary endpoint) in the context of important vascular 53 
determinants thereof (secondary endpoints) including blood pressure, pulse wave velocity 54 
(PWV), and aortic augmentation index (AIX) after acute consumption of cranberry juice with 55 
increasing amounts of (poly)phenols. The second major aim was to quantify novel cranberry-56 
derived (poly)phenol metabolites in plasma (tertiary endpoints) to link with vascular effects. 57 
 58 
59 
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SUBJECTS AND METHODS 60 
Intervention study subjects 61 
Ten healthy male volunteers from 18 to 35 years were recruited from the University of 62 
Duesseldorf and surrounding area. Health was ascertained by a routine clinical physical exam 63 
and specific cardiovascular history performed by a cardiovascular specialist (cardiology/vascular 64 
medicine). Manifest cardiovascular disease including coronary artery disease, cerebrovascular 65 
disease and peripheral artery disease, diabetes mellitus, acute inflammation, terminal renal 66 
failure, malignancies, and heart rhythm other than sinus were exclusion criteria.  The study flow 67 
is represented in Figure 1A. 68 
Study Design  69 
A 6-arm randomized, double blind, crossover, controlled intervention trial was conducted, where 70 
volunteers were asked to consume a cranberry juice drink or a macro- and micro-nutrient 71 
isocaloric control drink. FMD, peripheral blood pressure measurements and blood samples were 72 
taken before (baseline) and at 1, 2, 4, 6, and 8 h post-acute consumption of each of the 6 73 
intervention juice drinks (450 mL) on 6 different days separated by 1 week washout. PWV, AIX 74 
and central blood pressure were measured at 0, 1.5, 4, 6 and 8 hours post-consumption (Figure 75 
1B).  76 
Volunteers were instructed not to alter their usual dietary or fluid intake. Those selected for the 77 
study were asked to refrain from the following for 72 h prior to, and during, the study: 78 
consumption of polyphenol-rich foods including fruits, vegetables, cocoa, chocolate, coffee, tea 79 
and wine, intake of nitrate rich foods: leafy green vegetables and beetroot, participating in 80 
vigorous exercise (> 3 x 20 min/week) and consuming more than 168 g of alcohol (any form) per 81 
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week. Volunteers were also asked not to eat anthocyanin-rich foods such as berries or red wine 82 
for one week before starting (run-in) and until the completion of the study. Compliance to the 83 
diet and lifestyle restrictions was determined via 24 h-dietary recalls and via interview. Written 84 
informed consent was obtained from all subjects prior to their participation in the study.  85 
The primary end point was an improvement of endothelial vasodilator function as measured by 86 
FMD using high-resolution ultrasound. Secondary endpoints were improvements in key 87 
determinants of vascular function and included decreases in PWV, AIX, and blood pressure 88 
(peripheral and central) as determined automatically by a blood pressure monitoring system and 89 
applanation tonometry (Sphygmocor). Tertiary endpoints include the quantification of plasma 90 
cranberry-derived (poly)phenols and was subsequently correlated with the primary endpoint. 91 
During the study day, a low (poly)phenol meal was giving together with the test drink, and no 92 
other food or drink was allowed until after 8 hours post-consumption, except for water ad 93 
libitum.  94 
Office blood pressure was measured three times after 10 min of rest using an automated clinical 95 
digital sphygmomanometer (Dynamap, Tampa, FL, USA) with appropriately sized cuff placed 96 
around the upper arm at heart level.  97 
A qualified researcher enrolled participants on the study. Participants and researchers 98 
administering interventions and assessing study outcomes were blinded to the interventions.  An 99 
independent researcher generated the random allocation to treatment sequence (using a Williams 100 
design) and implemented the allocation sequence.  The study was conducted according to the 101 
guidelines laid down in the Declaration of Helsinki and all procedures involving human subjects 102 
were approved by the University of Duesseldorf Research Ethics Committee (ref: 14-012). The 103 
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study was also registered with the National Institutes of Health (NIH)-randomized trial records 104 
held on the NIH ClinicalTrials.gov website (NCT02517775). This study was conducted at the 105 
University of Duesseldorf from January to September 2015.   106 
Cranberry and control drinks 107 
Ocean Spray supplied the cranberry and control drinks. Volunteers were asked to consume a 108 
cranberry juice drink containing 409, 787, 1238, 1534, and 1910 mg of total polyphenols (TP) 109 
(equivalent to 25, 48, 76, 94, and 117% concentrated cranberry juice) or a macro- and micro-110 
nutrient isocaloric control drink which was indistinguishable in color and taste to the cranberry 111 
juice test drinks and contained 3 mg of TP. The 6 intervention drinks consisted of a total volume 112 
of 450 mL from cranberry juice and control drink. The (poly)phenol content of all test drinks is 113 
shown in Table 1 and the nutritional composition of control and the most concentrated drink in 114 
Table 2.  115 
Ultrasound measurements of arterial function and pulse wave velocity 116 
FMD was measured as previously described [10]. Briefly, the diameter and flow velocity of the 117 
brachial artery (BA) was measured using a 12 MHz transducer (Vivid I, GE, Frankfurt, 118 
Germany) and automatic edge-detection software (Brachial Analyzer, Medical Imaging 119 
Applications, Iowa City, IA, USA) yielding standard deviations of mean differences between 120 
repeated measurements of less than 1%. BA diameter was measured approximately 2 cm 121 
proximal to the elbow. Reactive hyperemia was induced by 5 min of distal lower arm with a 122 
sphygmomanometric cuff inflated to 250 mm Hg. After cuff deflation (0 sec), 20, 40, 60, and 80 123 
sec, the diameter was assessed and FMD calculated as maximal relative diameter gain relative to 124 
baseline. The FMD was expressed as (diametermax-diameterbaseline)/diameterbaseline * 100.  125 
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Central blood pressure parameters including AIX and PWV were measured by applanation 126 
tonometry using the SphygmoCor® system (AtCor Medical, West Ryde, Australia). Via a 127 
transfer function, the pressure waveform of the ascending aorta was synthesized. PWV was 128 
determined from measurements taken at the carotid and femoral artery as previously described 129 
[11]. 130 
Biochemical analyses 131 
The blood samples collected in EDTA/heparin tubes were spun (1700 x g; 15 min; 4ºC) 132 
immediately after collection.  Samples for (poly)phenol analysis were spiked with 2% formic 133 
acid. All samples were aliquoted and frozen at -80°C until analysis. All clinical chemistry 134 
parameters including total, LDL and HDL-cholesterol, tryglycerides (enzymatic photometric 135 
assay; RocheDiagnostics), HbA1c, glucose (hexokinase assay) and whole blood count (flow 136 
cytometry; Sysmex) were measured using standard techniques by the Institute for Clinical 137 
Chemistry, University Hospital Duesseldorf, Germany. 138 
UPLC-Q-TOF MS analysis of plasma (poly)phenols 139 
The identification and quantification of plasma (poly)phenol metabolites in plasma after 140 
cranberry juice consumption was performed as previously described using micro-elution solid 141 
phase extraction followed by UPLC-Q-TOF MS  [12].  142 
Materials 143 
All (poly)phenol metabolites (sulfates and glucuronides) were obtained from Toronto Research 144 
Chemicals (Toronto, Canada), except kaempferol-3-O-ß-D-glucuronide which was obtained 145 
from Extrasynthese (Genay, France). 1-Methylpyrogallol-O-sulfate, 2-methylpyrogallol-O-146 
sulfate, 4-methylcatechol-O-sulfate, 4-methylgallic-3-O-sulfate , catechol-O-sulfate , pyrogallol-147 
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O-1-sulfate , pyrogallol-O-2-sulfate and vanillic acid-4-O-sulfate were kindly provided by Dr 148 
Claudia Nunes dos Santos and Dr Rita Ventura and their synthesis has been described elsewhere 149 
[13]. All the polyphenol and phenolic acid aglycones were obtained from Sigma-Aldrich Co. 150 
(Steinheim, Germany) and 2-, 3- and 4-hydroxyhippuric acids were purchased from Enamine 151 
(Kiev, Ukraine). Acetic acid was from Carl Roth (Karlsruhe, Germany) and Oasis HLB µElution 152 
plates were from Waters (Eschborn, Germany). Milli-Q system (Merck KGaA, Darmstadt, 153 
Germany) ultra pure water was used. Unless otherwise stated, all chemicals and reagents were 154 
obtained from Sigma-Aldrich Co. (Steinheim, Germany).  155 
Power calculation and statistical analysis  156 
Power calculations were performed for the primary endpoint, change in FMD response. Power 157 
was based on the intra-individual variability of the operator who performed the FMD analysis 158 
(5% CV, SD=0.3). At 0.8 power, a 0.05 significance level and a mean FMD of 7.2%, the number 159 
of subjects required to detect a difference of 0.3% in the response of matched pairs in a crossover 160 
study is 10. This number is consistent with other studies carried out with similar endpoints and 161 
study design [14-16]. The characteristics of the study population are expressed as mean values 162 
and standard deviations. Results are presented as mean values and their standard error of means, 163 
and differences between responses are presented as mean values and 95 % confidence intervals. 164 
Differences in the outcome variables were compared by one-way ANOVA using Tukey post-hoc 165 
test. Data not normally distributed were compared with Wilcoxon test. Statistical analysis was 166 
performed with GraphPad Prism (version 6.00, GraphPad software, CA, US), and JMP Pro 167 
(version 11.0.0; SAS institute Inc., NC, US). Correlations are presented as Pearson’s r. 168 
169 
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RESULTS 170 
Baseline characteristics of the study population and tolerance of intervention: The baseline 171 
characteristics of young healthy non-obese males were all within normal limits (Table 3). The 172 
cardiovascular risk at baseline (10 year CAD risk) was low (1.0±0.5%), according to the 173 
Framingham risk score. All drinks were well tolerated by all subjects and no adverse events were 174 
reported. 175 
 176 
Dose- and time-dependent improvements in vascular function following cranberry juice 177 
consumption 178 
The single consumption of the test drinks containing between 409 and 1910 mg of TP but not the 179 
control drink led to a time-dependent increase in the primary endpoint, FMD. As depicted in 180 
Figure 2, FMD gradually increased after consumption of the cranberry juices with a maximum 181 
at 4h. FMD increased dose-dependently with maximal effects seen after drink containing 1 238 182 
mg TP. The median effective dose (ED50), was 436 mg (95% CI 226, 841 mg). When comparing 183 
changes in FMD after consumption of the cranberry juice drinks (409-1910 mg TP) with changes 184 
in FMD after consumption of the control drink, significantly greater improvements were 185 
observed at 1, 2, 4, 6, and 8 hours post-consumption of the juices containing 1910 and 1534 mg 186 
TP (p=0.0048, 0.0022, 0.0006, 0.0002, and 0.0080 for 1910 mg TP and p=0.0006, 0.0007, 187 
0.0017, 0.0062 and 0.0247 for 1534 mg TP, respectively); at 1, 2, 4, and 6 h for the juice 188 
containing 1238 mg TP (p=0.0455, 0.0173, 0.0140, 0.0058, respectively); at 1, 2, 6 and 8 h for 189 
the drink containing 787 mg TP (p=0.0017, 0.0173, 0.0113, 0.0452, respectively), and at 2 h for 190 
the drink containing 409 mg TP (p=0.0048) (Figure 2A).  191 
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The area under the curve of FMD % versus time after consumption of the cranberry juices was 192 
significantly higher (p=0.0257, 0.0312, 0.0046, 0.0028 for 787, 1238, 1534 and 1910 mg TP, 193 
respectively) than after consumption of the control drink except for the lower dose (409 mg TP) 194 
(Figure 2B). 195 
No significant results were observed when comparing changes in blood pressure, PWV or AIX 196 
after consumption of the cranberry drinks with changes after consumption of the control drink 197 
(data not shown). However, a significant decrease in central systolic blood pressure (CSBP) was 198 
observed at 6 h after consumption of the drink containing the largest amount of TP (1910 mg TP) 199 
when compared to baseline (97 ± 1.6 mm Hg versus 107 ± 2.6 mm Hg, p=0.0351). Central 200 
diastolic blood pressure and office blood pressure did not significantly change after any 201 
intervention. A significant decrease in AIX with respect to baseline was also observed at 1.5 and 202 
6 h post-consumption of the cranberry drink containing 1534 mg TP (-14 ± 3.2%, -13 ± 2.9% 203 
versus -4.2 ± 2.5%, p=0.0306 and 0.0483, respectively), and after 4 and 6 h post-consumption of 204 
drink containing 409 mg TP (-15 ± 3.4%, -16 ± 3.5% versus -6.1 ± 2.1%, p=0.0341 and 0.0342, 205 
respectively).  206 
 207 
Identification and quantification of novel phenolic metabolites after cranberry juice 208 
consumption 209 
Using authentic standards, we have recently reported the identification and quantification of 60 210 
(poly)phenol metabolites in the plasma of the volunteers participating in the study, with 43 of 211 
them being reported for the first time after consumption of cranberry juice [12]. Most 212 
metabolites were conjugated and non-conjugated phenolic acid compounds, with only 3 of them 213 
being flavonoid derivatives (kaempferol, kaempferol-3-O-ß-D-glucuronide, and quercetin-3-O-ß-214 
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D-glucuronide). Many of the individual compounds were absorbed in a dose-dependent manner, 215 
so the plasma concentration increased with increasing concentration of the cranberry juices 216 
(Figure 3). 217 
Novel cranberry phenolic metabolites correlate with vascular effects  218 
In order to link the circulating metabolites with vascular effects, we performed a correlation 219 
analysis with the increases in FMD at 1, 2, 4, 6, and 8 h as the dependent variable and all 220 
metabolites as independent variables. This analysis showed 12 phenolic metabolites that could 221 
predict the vascular effects (Table 4). Seven of them were cinnamic acid derivatives (caffeic 222 
acid, caffeic acid 4-O-ß-D-glucuronide, dihydro caffeic acid 3-O-sulfate, ferulic acid 4-O-sulfate, 223 
dihydroferulic acid 4-O-sulfate, dihydro isoferulic acid 3-O-sulfate, cinnamic acid), and 3 of 224 
them were benzoic acid derivatives (vanillic acid-4-O-sulfate, homovanillic acid sulfate, 4-225 
methylgallic-3-O-sulfate) (Figure 4). Quercetin 3-O-β-D-glucuronide was the only conjugated 226 
flavonoid that correlated with FMD. A proanthocyanidin/flavan-3-ol-derived metabolite, (4R)-5-227 
(3'-hydroxyphenyl)-γ-valerolactone-4'-O-sulfate, also correlated with FMD. Six metabolites 228 
correlated with the changes in FMD after 1 h post consumption, 9 metabolites correlated with 2 h 229 
values, 7 with 4 h values, 8 with 6 h values, and 6 with 8 h values (Table 4). The AUC of the 230 
concentration of all these metabolites in plasma correlated with the AUC of the FMD responses 231 
between 0 and 8 h (Pearson r = 0.510, p-value <0.0001).  232 
233 
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Discussion 234 
To our knowledge this is the first study that reports improvements in endothelial function after 235 
cranberry juice consumption in healthy individuals.  Only one study has tested the effect of 236 
cranberry on flow-mediated dilation in patients with CAD [5, 6] and with mixed results. The 237 
authors observed a significant improvement in FMD (1%) at 4 h after acute cranberry juice 238 
consumption (835 mg TP, 94 mg anthocyanins) [5]. In the same study, the authors showed in 239 
these CAD patients that daily cranberry juice consumption over 4 weeks did not confer any type 240 
of chronic effect i.e. FMD increase that is still present after an overnight fast. Our present study 241 
supports that indeed cranberry juice can induce strong immediate improvements in FMD of up to 242 
2.6% in healthy subjects over several hours after consumption. Results from recent meta-analyses 243 
have demonstrated that an increase in FMD of 1% translates into a decrease in CVD risk of 10-244 
13% [17-19]. Therefore, the average increase of 2% after cranberry juice consumption observed 245 
in the present study could be interpreted as a decrease of 20% in the risk of CVD. This, however, 246 
implies that the improvements are maintained over time potentially requiring regular repetitive 247 
consumptions of cranberry juice and/or other foods containing bioactives. Future long-term 248 
studies will determine whether positive effects persist with chronic consumption and if this 249 
indeed leads to health benefits in primary prevention and whether this is also true in a broader 250 
segment of the health population (generalizability). 251 
The current data present a basic understanding of cranberry (poly)phenol pharmacodynamics that 252 
was so far unknown. The FMD improvements observed after cranberry consumption followed a 253 
non-linear dose-dependency, with the linear part of the response curve after consumption of the 254 
cranberry juices containing 409 to 1238 mg TP and plateauing at higher intake amounts. This is 255 
in agreement with previous work from our group, where the dose-dependent effects of blueberry 256 
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(poly)phenol consumption were investigated [16]. The polyphenol intake needed to achieve half-257 
maximal effects (ED50) was found to be 482 mg, which is remarkably similar to the present 258 
study (436 mg TP), despite significant differences in the polyphenol profile of the test products. 259 
The tested blueberries had a higher content of anthocyanins and chlorogenic acid than the 260 
cranberry juices, which in turn had a higher proanthocyanidin content. Consistent with this, a 261 
meta-analysis has reported a non-linear dose-response for FMD after consumption of other 262 
polyphenol rich foods, where the FMD response increased in magnitude with increasing doses 263 
only in foods containing lower than 1,000 mg of total flavonoids and procyanidins per day [20]. 264 
While there is a clear intake-dependence with regards to total (poly)phenols, the relative 265 
contribution of individual compounds is less clear.  266 
In order to evaluate the role of cranberry (poly)phenols on vascular function, we investigated the 267 
plasma levels of phenolic metabolites after cranberry consumption. Up to now, only few studies 268 
have investigated the bioavailability of cranberry (poly)phenols [21-26], and none of them had 269 
used authentic standards of phase II metabolites for quantification. We have recently 270 
demonstrated the presence of 60 cranberry-derived phenolic metabolites in human plasma after 271 
cranberry juice consumption, 43 of them novel [12]. In a correlation analysis, we now 272 
investigated which of them could explain the observed vascular effects. Of these, 12 phenolic 273 
compounds were found to correlate with the vascular response, of which only one was a 274 
flavonoid conjugate, coming from the flavonols present in cranberry (quercetin-3-O-ß-D-275 
glucuronide). The valerolactone sulfate is very likely to derive from proanthocyanidins and 276 
flavan-3-ols, as it has been reported after consumption of proanthocyanidin-rich foods such as 277 
cocoa flavanols and tea [27-29]. The other ones were non-specific phenolic metabolites 278 
(cinnamic, benzoic and phenylacetic acid derivatives) that could originate from any of the 279 
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(poly)phenols present in the cranberry juice, for example by direct absorption of 280 
hydroxycinnamic acids, breakdown of anthocyanins, or gut microbial metabolism of 281 
proanthocyanidins. When calculating the AUC of all those metabolites together, a significant 282 
correlation was also found with the AUC of the FMD response. Thus, our results indicate that 283 
several (poly)phenols present in cranberry juice may lead to a complex profile of candidate 284 
bioactives in plasma that were so far not in the focus of research. These candidate bioactives may 285 
synergistically contribute to the improvements in endothelial function after cranberry juice 286 
consumption. This, however, needs to be shown in future studies establishing causality and 287 
identifying the potential underlying mechanism(s) of action also keeping in mind that other 288 
nutrients or bioactives present in cranberry may contribute to the observed vascular effects. With 289 
regards to these future studies, the observed concentrations of compounds being associated with 290 
vascular effects, which ranged between low nM and low µM [12], need to be taken into 291 
considerations and used for evaluation. 292 
Although the mechanism(s) of action of (poly)phenols in the vascular system have not yet been 293 
elucidated, the improvements in endothelial function observed here are likely to involve an 294 
increase in nitric oxide (NO) bioavailability, as it is known that FMD is at least partially, NO 295 
mediated [30, 31]. We have recently shown that blueberry (poly)phenol metabolites inhibited 296 
NADPH oxidase activity and correlated with FMD improvements and plasma phenolic 297 
metabolites [16], so it is possible that plasma cranberry phenolic metabolites improved NO 298 
bioavailability via inhibition of NADPH oxidase activity. Indeed, most of the metabolites that 299 
correlated with the FMD, such as ferulic, caffeic, vanillic acid derivatives or quercetin 300 
glucuronide have structural homologies to the pharmacologic NADPH oxidase inhibitor apocynin 301 
[32] and have been proposed as potent NAPDH oxidase inhibitors in endothelial cells [33, 34]. 302 
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However, most metabolites which correlated with vascular responses in the present study have 303 
not been subjected to mechanistic studies up until now because they are not commercially 304 
available. It was recently shown that both quercetin and its major metabolites, including quercetin 305 
glucuronide, are able to confer an acute endothelial protective effect via activation of AMPK 306 
pathway, which can induce endothelial nitric oxide synthase (eNOS) activation, and, therefore, 307 
NO production [35]. It is also likely that other potential mechanisms of action may play a role in 308 
the vascular effects of (poly)phenols, such as regulation of heme oxigenase-1 and Nrf2 signaling 309 
[36].  310 
Conclusion 311 
(Poly)phenols in cranberry juice can improve vascular function in healthy males and this is linked 312 
to the presence of specific newly identified plasma metabolites. The nutritional relevance of our 313 
findings is underscored by the fact that significant and dose-dependent improvements in 314 
endothelial functions were seen even after the consumption of widely available single (25% 315 
concentrated) and double strength (48% concentrated) cranberry juices.  316 
317 
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 Table 1. (Poly)phenol content of the cranberry and placebo drinks, expressed in mg/450 mL 
(single dose).   
  
Control 
drink 
409 
mg TP 
 787 
mg TP 
 1238 
mg TP 
 1534 
mg TP 
 1910 
mg TP 
Phenolic acids 2.7 12.8 24.5 35.3 48.6 59.2 
Benzoic acid  2.3 4.5 7.8 11.1 15.5 17.1 
Salicylic acid (2-hydroxybenzoic acid) 0.0 0.0 0.1 0.1 0.2 0.3 
Protocatechuic acid (3,4- 
dihydroxybenzoic acid) 0.0 0.4 1.1 1.8 2.4 3.1 
Gallic acid (3,4,5-trihydroxybenzoic acid) 0.0 0.0 0.1 0.1 0.2 0.2 
Vanillic acid (4-hydroxy-3-
methoxybenzoic acid) 0.0 0.4 1.0 1.1 1.7 3.2 
t-Cinnamic acid 0.3 0.6 1.0 1.8 2.1 2.6 
p-Coumaric acid (4-hydroxycinnamic 
acid) 0.0 3.5 6.9 9.6 13.3 16.2 
Caffeic acid (3,4-dihydroxycinnamic acid) 0.0 0.6 1.2 1.9 2.5 3.1 
Ferulic acid (3-methoxy-4-
hydroxycinnamic acid) 0.0 0.0 0.0 0.3 0.5 0.6 
Chlorogenic acid 0.0 2.6 5.2 7.5 10.3 12.8 
Flavan-3-ols 0.0 2.5 5.0 6.8 10.1 12.3 
Catechin 0.0 0.2 0.5 0.8 1.2 1.5 
Epicatechin 0.0 2.2 4.5 6.0 8.9 10.8 
Flavonols 0.2 14.5 31.3 48.9 62.8 76.9 
Quercetin 0.0 4.0 8.5 15.5 18.2 20.5 
Quercitrin (Quercetin-3-O-rhamnoside) 0.0 2.2 4.6 6.5 8.1 10.7 
Hyperoside (Quercetin-3-O-galactoside) 0.0 2.0 3.9 5.5 7.2 9.4 
Myricetin 0.2 4.0 8.2 11.2 14.7 18.4 
Myricetrin (Myricetin-3-O-rhamnoside)  0.0 1.6 3.2 4.8 6.4 7.4 
Myricetin-3-O-galactoside  0.0 0.7 2.9 5.4 8.2 10.4 
Anthocyanins 0.0 6.8 16.2 23.2 26.3 32.3 
Cyanidin-3-arabinoside 0.0 3.7 6.8 9.5 12.1 14.7 
Cyanidin-3-galactoside 0.0 0.0 1.7 2.4 2.9 3.6 
Cyanidin-3-glucoside 0.0 0.0 0.0 0.0 0.0 0.0 
Peonidin-3-arabinoside 0.0 2.0 2.1 3.6 7.0 8.4 
Peonidin-3-galactoside 0.0 1.1 2.0 2.9 3.3 4.5 
Peonidin-3-glucoside 0.0 0.0 0.0 4.8 1.0 1.1 
Proanthocyanidins       
BL-DMAC 0.0 124.8 242.5 278.2 420.9 485.5 
OSC-DMAC 0.0 372.6 710.5 1124.0 1386.3 1729.1 
Total Phenolics (Folin method) 0.0 180.0 517.5 778.5 1318.5 1521.0 
Total sum (poly)phenols 2.9 409.0 787.5 1238.1 1534.1 1909.9 
% Cranberry juice  0.0 25.1 48.2 75.8 94.0 117.0 
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Table 2. Nutritional analysis of the control drink and the most concentrated cranberry juice 
(1910 mg TP) per serving size (450 mL). 
  Control drink Drink 1910 mg TP 
Energy (kcal) 208 200 
Energy from fat (kcal) <4.72 <4.72 
Total fat (g) <0.009 <0.009 
Total carbohydrates (g) 50.9 49.5 
Total dietary fiber (g) <3.54 <3.54 
Total sugars (g) 42 35 
Protein (g) 0.90 0.75 
Vitamin C (mg) <4.7 <4.7 
Moisture (g) 419 421 
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Table 3: Baseline clinical characteristics study population (n=10).   
 Mean ± SD 
Age (years)  24 ± 2 
Weight (kg) 79 ± 8 
BMI (kg/m2) 24 ± 2 
Total cholesterol (mg/dL) 149 ± 33 
LDL cholesterol (mg/dL) 90 ± 31 
HDL cholesterol (mg/dL) 49 ± 7 
Triglycerides (mg/dL) 66 ± 17 
Glucose (mg/dL) 88 ± 5 
GOT  (U/L) 24 ± 5 
GPT  (U/L) 22 ± 6 
-GT (U/L) 19 ± 7 
Uric acid (mg/dL) 6 ± 1 
Creatinine (mg/dL) 1.0 ± 0.1 
Bilirubin (mg/dL) 0.5 ± 0.3 
Heart rate (bpm) 60 ± 8 
Systolic blood pressure (mm Hg) 119 ± 8 
Diastolic blood pressure (mm Hg) 66 ± 10 
FMD (%) 6.0 ± 1.4 
Pulse wave velocity (m/s) 5.3 ± 0.8 
Augmentation Index (%) -4.3 ± 14 
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Table 4: Significant correlations (p<0.05) between plasma cranberry-derived (poly)phenol 
metabolites and changes in FMD at different timepoints after consumption of cranberry juice 
with respect to baseline at 0 h (n=10). Correlations correspond to Pearson’s r. *p<0.05; #p<0.01; 
§p<0.001. 
 
 
Metabolites correlating with 
ΔFMD at respective timepoints 
Pearson’s r 
1h 2h 4h 6h 8h 
(4R)-5-(3'-hydroxyphenyl)-γ-
valerolactone-4’-O-sulfate 
      0.325*         0.345* 
4-Methylgallic acid-3-O-sulfate 0.297* 0.460# 0.332*   
Caffeic acid    0.682§*  0.337* 
Caffeic acid 4-O-ß-D-glucuronide   0.320*    
Cinnamic acid   0.303*    
Dihydro caffeic acid 3-O-sulfate      0.395# 0.470§ 
Dihydro ferulic acid 4-O-sulfate    0.405# 0.477§ 
Dihydro isoferulic acid 3-O-sulfate 0.367# 0.397# 0.338* 0.371# 0.471§ 
Ferulic acid 4-O-sulfate 0.408# 0.437# 0.362# 0.369# 0.461§ 
Homovanillic acid sulfate  0.378# 0.428# 0.430# 0.455# 0.339* 
Quercetin-3-O-ß-D-glucuronide 0.275* 0.423# 0.308* 0.371#  
Vanillic acid-4-O-sulfate 0.387# 0.494§ 0.364# 0.347*  
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Figure captions 
 
Figure 1: A) Study flow (n=10) and B) study design 
Figure 2.  A) Changes in flow-mediated dilation (FMD) respect to baseline and B) changes in 
areas under the curve of the FMD response over time after consumption of the cranberry juice 
drinks containing 409, 787, 1,238, 1,534, and 1,910 mg of total (poly)phenols and the control 
drink (n=10).*p<0.05 significantly different from control. 
Figure 3. Examples of time-course of (poly)phenols plasma concentrations after consumption of 
cranberry juice drinks containing 409, 787, 1,238, 1,534, and 1,910 mg of total (poly)phenols 
and a control drink (n=10):, (A) ferulic acid 4-O-sulfate, (B) vanillic acid-4-O-sulfate, (C) (4R)-
5-(3'-hydroxyphenyl)-γ-valerolactone-4’-O-sulfate, (D) 4-methylgallic acid-3-O-sulfate, (E) 
quercetin-3-O-β-D-glucuronide and F) caffeic acid -4-O-ß-D-glucuronide. Symbols are means, 
and error bars correspond to SEM.  
Figure 4. Structures of plasma (poly)phenol metabolites that correlated with changes in FMD 
after cranberry juice consumption. 
 
 
 
 
  
